Aktiesnakken — September 2013
-
Super spændende artikel med Aabo og Bowers omhandlende hele den danske bioteksektor: http://medwatch.dk/secure/Medicinal___Biotek/article5913681.ece
-
Kan han vel ikke undgå efter Jans udmeldinger til CC'en
-
Aabos bash gik jo på at Arzerra data ikke så gode ud samt at han troede DLBLC ville fejle. At jan siger de vil vise data der er bedre end GA101 og han udtaler det så tydeligt overbeviser jo de fleste
-
Handelsbanken laver en intern handel på 21.000 stk. genmab !
-
jo det vil jeg også skyde på
-
ja SOLS 20.000 ADR er jo 40.000 aktier handlet
-
Til dem som kun kører chat er der link til et lille indlæg på sitet her: http://www.market-trends.net/blog/flere-saesonvariationer.html. Så er alt spammet 100%
-
-
Karo Bio achieves first milestone in Pfizer collaboration
STOCKHOLM, 5 September 2013 – The collaboration between Karo Bio AB and Pfizer Inc. has successfully resulted in a significant achievement within the...
GlobeNewswire News Room (www.globenewswire.com)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind